Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Theratechnologies Inc > New Corporate Presentation Out
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(15)
•••
Comment by PinnacleXon Oct 17, 2022 4:40pm
82 Views
Post# 35029991

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Corporate Presentation Out

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Corporate Presentation Out
PWIB123 wrote: I'm willing to wait and continue to hope.  I'm tired of losing money and not seeing the executives at THTX generate a level of confidence and restore value in the stock of the company.  I'm not expecting the big pay day tomorrow, but I was expecting they begin generating a gradual increase in value from awareness, de-risking, and additional value proposition as they work through the different stages of the clinical trials.  I never expected a straight drop to the bottom and zero value creation.

Bucknelly21 wrote: Im tired of hoping... these guys keep investors on there heels every quater 





In the states you can sue for that and thats what Id like to see. They destroyed value every week.  
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities